Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Liver Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 80 articles: HTML format

Single Articles

May 2020
1. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
   Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
   J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
   PubMed     Abstract available
   
   
   February 2020
2. KUDO M, Okusaka T, Motomura K, Ohno I, et al
   Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
   J Gastroenterol. 2020 Feb 27. pii: 10.1007/s00535-020-01668.
   PubMed     Abstract available
   
   
   
3. TAKEHARA T, Chayama K, Kurosaki M, Yatsuhashi H, et al
   JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
   J Gastroenterol. 2020 Feb 17. pii: 10.1007/s00535-020-01672.
   PubMed     Abstract available
   
   
   January 2020
4. KAJI K, Yoshiji H
   Can portal hypertension and hepatic decompensation be predicted?
   J Gastroenterol. 2020 Jan 21. pii: 10.1007/s00535-020-01669.
   PubMed    
   
   
   December 2019
5. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
   The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
   J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
   PubMed     Abstract available
   
   
   November 2019
6. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
   Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
   J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
   PubMed     Abstract available
   
   
   
7. YAMASHITA T, Kudo M, Ikeda K, Izumi N, et al
   REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
   J Gastroenterol. 2019 Nov 12. pii: 10.1007/s00535-019-01642.
   PubMed     Abstract available
   
   
   October 2019
8. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
   Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
   J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
   PubMed     Abstract available
   
   
   September 2019
9. KIM D, Kim W, Joo SK, Han J, et al
   Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
   J Gastroenterol. 2019 Sep 18. pii: 10.1007/s00535-019-01628.
   PubMed     Abstract available
   
   
   
10. ESO Y, Shimizu T, Takeda H, Takai A, et al
    Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    J Gastroenterol. 2019 Sep 7. pii: 10.1007/s00535-019-01620.
    PubMed     Abstract available
    
    
    
11. PUIGVEHI M, Londono MC, Torras X, Lorente S, et al
    Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.
    J Gastroenterol. 2019 Sep 6. pii: 10.1007/s00535-019-01619.
    PubMed     Abstract available
    
    
    
12. NAMBA M, Hiramatsu A, Aikata H, Kodama K, et al
    Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    J Gastroenterol. 2019 Sep 4. pii: 10.1007/s00535-019-01623.
    PubMed     Abstract available
    
    
    August 2019
13. TATEISHI R, Koike K
    Changing etiology of hepatocellular carcinoma.
    J Gastroenterol. 2019 Aug 31. pii: 10.1007/s00535-019-01622.
    PubMed    
    
    
    
14. HUO TI, Ho SY
    Evolution of hepatocellular carcinoma: non-B, non-C and beyond.
    J Gastroenterol. 2019 Aug 30. pii: 10.1007/s00535-019-01621.
    PubMed    
    
    
    
15. EBADI M, Bhanji RA, Mazurak VC, Montano-Loza AJ, et al
    Sarcopenia in cirrhosis: from pathogenesis to interventions.
    J Gastroenterol. 2019 Aug 7. pii: 10.1007/s00535-019-01605.
    PubMed     Abstract available
    
    
    July 2019
16. SHIMADA S, Tanaka S
    A new era for understanding genetic evolution of multistep carcinogenesis.
    J Gastroenterol. 2019;54:667-668.
    PubMed     Abstract available
    
    
    June 2019
17. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    PubMed     Abstract available
    
    
    April 2019
18. MANO Y, Yoshio S, Shoji H, Tomonari S, et al
    Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
    J Gastroenterol. 2019 Apr 2. pii: 10.1007/s00535-019-01579.
    PubMed     Abstract available
    
    
    March 2019
19. SUMIDA Y, Yoneda M, Okanoue T
    Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01573.
    PubMed    
    
    
    
20. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Response to the letter by Sumida et al. regarding our manuscript "Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease".
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01574.
    PubMed    
    
    
    
21. NAGANUMA A, Chayama K, Notsumata K, Gane E, et al
    Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
    J Gastroenterol. 2019 Mar 13. pii: 10.1007/s00535-019-01569.
    PubMed     Abstract available
    
    
    
22. KADO A, Tsutsumi T, Enooku K, Fujinaga H, et al
    Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    J Gastroenterol. 2019 Mar 4. pii: 10.1007/s00535-019-01565.
    PubMed     Abstract available
    
    
    
23. SEKO Y
    Reply to: Sarcopenia definition in patients with NAFLD.
    J Gastroenterol. 2019;54:298.
    PubMed    
    
    
    
24. PENG TC
    Sarcopenia definition in patients with NAFLD.
    J Gastroenterol. 2019;54:297.
    PubMed    
    
    
    February 2019
25. TSUSHIMA K, Tsuge M, Hiraga N, Uchida T, et al
    Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice.
    J Gastroenterol. 2019 Feb 21. pii: 10.1007/s00535-019-01558.
    PubMed     Abstract available
    
    
    
26. KOBAYASHI M, Kudo M, Izumi N, Kaneko S, et al
    Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    J Gastroenterol. 2019 Feb 20. pii: 10.1007/s00535-019-01554.
    PubMed     Abstract available
    
    
    
27. KIM SK, Takeda H, Takai A, Matsumoto T, et al
    Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    J Gastroenterol. 2019 Feb 12. pii: 10.1007/s00535-019-01555.
    PubMed     Abstract available
    
    
    
28. KANNO M, Kawaguchi K, Honda M, Horii R, et al
    Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    J Gastroenterol. 2019 Feb 1. pii: 10.1007/s00535-019-01551.
    PubMed     Abstract available
    
    
    
29. SHIRABE K, Bekki Y, Gantumur D, Araki K, et al
    Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis".
    J Gastroenterol. 2019;54:206-207.
    PubMed    
    
    
    
30. TATEISHI R, Seike M, Kudo M, Tamai H, et al
    A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    J Gastroenterol. 2019;54:171-181.
    PubMed     Abstract available
    
    
    
31. MIZUNO N, Seko Y, Kataoka S, Okuda K, et al
    Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease.
    J Gastroenterol. 2019;54:160-170.
    PubMed     Abstract available
    
    
    January 2019
32. BRAR G, Tsukamoto H
    Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science.
    J Gastroenterol. 2019 Jan 14. pii: 10.1007/s00535-018-01542.
    PubMed     Abstract available
    
    
    
33. KIMURA K
    Long-awaited treatment for hepatitis C virus decompensated cirrhosis.
    J Gastroenterol. 2019 Jan 1. pii: 10.1007/s00535-018-01538.
    PubMed    
    
    
    November 2018
34. RAKSAYOT M, Chuaypen N, Khlaiphuengsin A, Pinjaroen N, et al
    Independent and additive effects of PNPLA3 and TM6SF2 polymorphisms on the development of non-B, non-C hepatocellular carcinoma.
    J Gastroenterol. 2018 Nov 30. pii: 10.1007/s00535-018-01533.
    PubMed     Abstract available
    
    
    
35. TATEISHI R, Uchino K, Fujiwara N, Takehara T, et al
    A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.
    J Gastroenterol. 2018 Nov 29. pii: 10.1007/s00535-018-1532.
    PubMed     Abstract available
    
    
    
36. YAMADA N, Mizuta K
    Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia.
    J Gastroenterol. 2018 Nov 9. pii: 10.1007/s00535-018-1523.
    PubMed    
    
    
    October 2018
37. IIO E, Matsuura K, Shimada N, Atsukawa M, et al
    TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
    J Gastroenterol. 2018 Oct 31. pii: 10.1007/s00535-018-1526.
    PubMed     Abstract available
    
    
    
38. PARK HE, Lee H, Choi SY, Kwak MS, et al
    Clinical significance of hepatic steatosis according to coronary plaque morphology: assessment using controlled attenuation parameter.
    J Gastroenterol. 2018 Oct 4. pii: 10.1007/s00535-018-1516.
    PubMed     Abstract available
    
    
    September 2018
39. TAKEHARA T, Sakamoto N, Nishiguchi S, Ikeda F, et al
    Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    J Gastroenterol. 2018 Sep 10. pii: 10.1007/s00535-018-1503.
    PubMed     Abstract available
    
    
    July 2018
40. SHIMA T, Uto H, Ueki K, Kohgo Y, et al
    Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.
    J Gastroenterol. 2018 Jul 13. pii: 10.1007/s00535-018-1494.
    PubMed     Abstract available
    
    
    June 2018
41. HUANG R, Wang J, Xia J, Hao Y, et al
    Potential clinical application of strain elastography in chronic liver diseases.
    J Gastroenterol. 2018;53:795-796.
    PubMed    
    
    
    
42. TAJIRI K, Kawai K, Sugiyama T
    Reply to "Letter to Editor submitted by Rui Huang et al. entitled potential clinical application of strain elastography in chronic liver diseases".
    J Gastroenterol. 2018;53:797-798.
    PubMed    
    
    
    May 2018
43. ENOOKU K, Kondo M, Fujiwara N, Sasako T, et al
    Hepatic IRS1 and ss-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
    J Gastroenterol. 2018 May 10. pii: 10.1007/s00535-018-1472.
    PubMed     Abstract available
    
    
    
44. ORIMO T, Kamiyama T, Mitsuhashi T, Kamachi H, et al
    Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2018 May 2. pii: 10.1007/s00535-018-1469.
    PubMed     Abstract available
    
    
    April 2018
45. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
    PubMed     Abstract available
    
    
    
46. YAGI M, Tanaka A, Namisaki T, Takahashi A, et al
    Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study.
    J Gastroenterol. 2018 Apr 16. pii: 10.1007/s00535-018-1465.
    PubMed     Abstract available
    
    
    February 2018
47. YONEDA M, Imajo K, Takahashi H, Ogawa Y, et al
    Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.
    J Gastroenterol. 2018;53:181-196.
    PubMed     Abstract available
    
    
    
48. NAKAHARA T, Hyogo H, Ono A, Nagaoki Y, et al
    Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease.
    J Gastroenterol. 2018;53:269-280.
    PubMed     Abstract available
    
    
    December 2017
49. SHINKAI N, Nojima M, Iio E, Matsunami K, et al
    High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    J Gastroenterol. 2017 Dec 29. pii: 10.1007/s00535-017-1424.
    PubMed     Abstract available
    
    
    
50. VITALE G, Gitto S, Raimondi F, Mattiaccio A, et al
    Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing.
    J Gastroenterol. 2017 Dec 13. pii: 10.1007/s00535-017-1423.
    PubMed     Abstract available
    
    
    November 2017
51. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
    A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
    J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
    PubMed     Abstract available
    
    
    
52. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Abstract available
    
    
    October 2017
53. KOYAMA N, Yamazaki T, Kanetsuki Y, Hirota J, et al
    Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 30. doi: 10.1007/s00535-017-1398.
    PubMed     Abstract available
    
    
    
54. NAKAO M, Nakayama N, Uchida Y, Tomiya T, et al
    Nationwide survey for acute liver failure and late-onset hepatic failure in Japan.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1394.
    PubMed     Abstract available
    
    
    
55. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Abstract available
    
    
    September 2017
56. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Abstract available
    
    
    
57. IMPERATORE N, Tortora R, Testa A, Gerbino N, et al
    Erratum to: Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Sep 19. doi: 10.1007/s00535-017-1393.
    PubMed     Abstract available
    
    
    August 2017
58. KAWAGUCHI K, Honda M, Ohta H, Terashima T, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    J Gastroenterol. 2017 Aug 28. doi: 10.1007/s00535-017-1386.
    PubMed     Abstract available
    
    
    
59. IMPERATORE N, Tortora R, Anna T, Gerbino N, et al
    Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Aug 19. doi: 10.1007/s00535-017-1381.
    PubMed     Abstract available
    
    
    
60. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Abstract available
    
    
    
61. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Abstract available
    
    
    
62. IKEDA M, Kudo M, Aikata H, Nagamatsu H, et al
    Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    J Gastroenterol. 2017 Aug 1. doi: 10.1007/s00535-017-1374.
    PubMed     Abstract available
    
    
    July 2017
63. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Abstract available
    
    
    
64. SEKO Y, Sumida Y, Sasaki K, Itoh Y, et al
    Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    J Gastroenterol. 2017 Jul 1. doi: 10.1007/s00535-017-1364.
    PubMed     Abstract available
    
    
    June 2017
65. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Abstract available
    
    
    
66. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Abstract available
    
    
    
67. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Abstract available
    
    
    May 2017
68. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352.
    PubMed    
    
    
    
69. OBA A, Kudo A, Akahoshi K, Kishino M, et al
    A simple morphological classification to estimate the malignant potential of pancreatic neuroendocrine tumors.
    J Gastroenterol. 2017 May 9. doi: 10.1007/s00535-017-1349.
    PubMed     Abstract available
    
    
    
70. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348.
    PubMed     Abstract available
    
    
    April 2017
71. KIM TJ, Sinn DH, Min YW, Son HJ, et al
    A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease.
    J Gastroenterol. 2017 Apr 5. doi: 10.1007/s00535-017-1337.
    PubMed     Abstract available
    
    
    
72. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Abstract available
    
    
    March 2017
73. CAI X, Hayashi S, Fang C, Hao S, et al
    Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    J Gastroenterol. 2017 Mar 31. doi: 10.1007/s00535-017-1332.
    PubMed     Abstract available
    
    
    
74. ZHANG AY, Lai CL, Huang FY, Seto WK, et al
    Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.
    J Gastroenterol. 2017 Mar 28. doi: 10.1007/s00535-017-1334.
    PubMed     Abstract available
    
    
    
75. KISHIDA Y, Okubo H, Ohno H, Oki K, et al
    Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    J Gastroenterol. 2017 Mar 27. doi: 10.1007/s00535-017-1331.
    PubMed     Abstract available
    
    
    
76. HASEBE T, Tanaka H, Sawada K, Nakajima S, et al
    Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.
    J Gastroenterol. 2017;52:341-351.
    PubMed     Abstract available
    
    
    February 2017
77. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Abstract available
    
    
    
78. MORIO R, Hyogo H, Hatooka M, Morio K, et al
    The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    J Gastroenterol. 2017;52:253-262.
    PubMed     Abstract available
    
    
    
79. MIYAKE T, Hirooka M, Yoshida O, Furukawa S, et al
    Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.
    J Gastroenterol. 2017;52:237-244.
    PubMed     Abstract available
    
    
    June 2016
80. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: